<DOC>
	<DOCNO>NCT02261389</DOCNO>
	<brief_summary>The main purpose follow-up asymptomatic breast cancer patient adjuvant treatment detect breast cancer recurrence metastatic disease.The aim trial verify , asymptomatic patient , serial measurement serum CEA CA 15.3 , diagnostic imaging procedure ( 18FDG-PET ) perform case critical increase serum CEA CA 15.3 level , anticipate diagnosis breast cancer local distant recurrence compare usual follow-up practice .</brief_summary>
	<brief_title>Follow-up Early Breast Cancer Dynamic Evaluation CEA CA 15.3 Followed 18FDG-PET</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>Male female ≥18 year . Histologically confirm stage IIII epithelial breast cancer . Adequate surgery breast axilla : 1. patient must undergo either total mastectomy breast conserve surgery 2. surgical margin resect specimen must histologically free invasive tumor . Signed informed consent obtain prior studyspecific procedure . Histologically confirm stage 0 epithelial breast cancer ( carcinoma situ ) . Special histology high low risk relapse ( i.e . sarcoma tubular carcinoma ) T1a T1b tumor follow characteristic : G12 N0 RE &gt; 10 % , RPg &gt; 10 % HER2 negative Ki67≤14 % Evidence distant metastasis Patients participate clinical trial require followup equal standard Previous history cancer within 5 year randomization ( except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , stage I uterine cancer , nonbreast malignancy outcome similar mention )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>follow-up</keyword>
	<keyword>tumor marker</keyword>
</DOC>